Tisdag 12 November | 23:45:13 Europe / Stockholm

Bifogade filer

Prenumeration

Kalender

Tid*
2025-05-08 08:00 Kvartalsrapport 2025-Q1
2025-05-05 - Årsstämma
2025-02-21 08:00 Bokslutskommuniké 2024
2024-10-24 - Kvartalsrapport 2024-Q3
2024-08-28 - Kvartalsrapport 2024-Q2
2024-05-16 - Kvartalsrapport 2024-Q1
2024-05-03 - X-dag ordinarie utdelning XBRANE 0.00 SEK
2024-05-02 - Årsstämma
2024-02-26 - Bokslutskommuniké 2023
2024-02-22 - Extra Bolagsstämma 2024
2023-11-30 - Kvartalsrapport 2023-Q3
2023-08-29 - Kvartalsrapport 2023-Q2
2023-05-31 - Kvartalsrapport 2023-Q1
2023-05-05 - X-dag ordinarie utdelning XBRANE 0.00 SEK
2023-05-04 - Årsstämma
2023-02-17 - Bokslutskommuniké 2022
2022-10-28 - Kvartalsrapport 2022-Q3
2022-07-22 - Kvartalsrapport 2022-Q2
2022-05-06 - X-dag ordinarie utdelning XBRANE 0.00 SEK
2022-05-05 - Kvartalsrapport 2022-Q1
2022-05-05 - Årsstämma
2022-02-24 - Bokslutskommuniké 2021
2021-10-29 - Kvartalsrapport 2021-Q3
2021-08-13 - Kvartalsrapport 2021-Q2
2021-05-07 - X-dag ordinarie utdelning XBRANE 0.00 SEK
2021-05-06 - Årsstämma
2021-05-06 - Kvartalsrapport 2021-Q1
2021-02-26 - Bokslutskommuniké 2020
2020-11-13 - Kvartalsrapport 2020-Q3
2020-09-22 - Extra Bolagsstämma 2020
2020-08-21 - Kvartalsrapport 2020-Q2
2020-06-22 - X-dag ordinarie utdelning XBRANE 0.00 SEK
2020-06-18 - Årsstämma
2020-05-14 - Årsstämma
2020-05-13 - Kvartalsrapport 2020-Q1
2020-02-28 - Bokslutskommuniké 2019
2019-11-15 - Kvartalsrapport 2019-Q3
2019-08-23 - Kvartalsrapport 2019-Q2
2019-06-18 - Extra Bolagsstämma 2019
2019-05-17 - X-dag ordinarie utdelning XBRANE 0.00 SEK
2019-05-16 - Årsstämma
2019-05-14 - Kvartalsrapport 2019-Q1
2019-02-28 - Bokslutskommuniké 2018
2018-11-16 - Kvartalsrapport 2018-Q3
2018-08-24 - Kvartalsrapport 2018-Q2
2018-05-25 - X-dag ordinarie utdelning XBRANE 0.00 SEK
2018-05-14 - Kvartalsrapport 2018-Q1
2018-04-03 - Extra Bolagsstämma 2018
2018-02-28 - Bokslutskommuniké 2017
2017-11-13 - Kvartalsrapport 2017-Q3
2017-08-31 - Kvartalsrapport 2017-Q2
2017-05-19 - X-dag ordinarie utdelning XBRANE 0.00 SEK
2017-05-18 - Kvartalsrapport 2017-Q1
2017-05-18 - Årsstämma
2017-03-07 - Kapitalmarknadsdag 2017
2017-02-27 - Bokslutskommuniké 2016
2016-11-21 - Kvartalsrapport 2016-Q3
2016-08-22 - Kvartalsrapport 2016-Q2
2016-05-27 - Kvartalsrapport 2016-Q1
2016-05-27 - X-dag ordinarie utdelning XBRANE 0.00 SEK
2016-05-26 - Årsstämma
2016-02-18 - Bokslutskommuniké 2015
2015-10-23 - Kvartalsrapport 2015-Q3

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
Xbrane Biopharma är verksamt inom bioteknik. Bolaget är specialiserat inom forskning och utveckling av läkemedel för behandling av kritiska sjukdomar. Idag är verksamheten inriktad mot forskning inom mikrosfärisk teknologi och inom utvecklingen av proteinmolekyler. Produkterna används vid behandling utav prostatacancer och endometrios, samt vid sällsynta och allvarliga ögonsjukdomar. Bolagets huvudkontor ligger i Solna.
2023-02-17 08:00:00

Xbrane Biopharma AB’s (publ.) (”Xbrane”)Year-end report 2022 is now available on the Company’s website, www.xbrane.com.

Financial overview fourth quarter 2022

  • Revenue amounted to SEK 17.3 m (2.8).
  • Other operating income was SEK 0.5 m (1.7).
  • EBITDA amounted to SEK –50.7 m (–28.2).
  • R&D costs amounted to SEK –59.5 m (–28.9), corresponding to 82 percent (79) of total operating costs.
  • The loss for the period was SEK –60.7 m (–32.5).
  • Earnings per share was SEK –2.25 (–1.32).
  • Cash and cash equivalents at the end of the period amounted to SEK 194.0 m (295.2).

Financial overview full-year 2022

  • Revenue amounted to SEK 57.6 m (10.7).
  • Other operating income was SEK 20.9 m (4.8).
  • EBITDA amounted to SEK –149.6 m (–168.4).
  • R&D costs amounted to SEK –199.6 m (–160.6), corresponding to 82 percent (82) of total operating costs.
  • The loss for the period was SEK –172.5 m (–188.4).
  • Earnings per share was SEK –6.75 (–7.98).
  • Cash and cash equivalents at the end of the period amounted to SEK 194.0 m (295.2).
  • The Board of Directors proposes that no dividend be paid for the financial year 2022.

Figures in parentheses refer to the corresponding period last year.

Significant events in the fourth quarter 2022

  • After authorization from the annual general meeting on May 5, 2022, the company announced and carried out a directed share issue of 2,363,112 new shares at a subscription price of SEK 72 per share. Through the directed new issue, net cash of around SEK 170 m before transaction costs was realized.
  • The European Commission granted marketing authorization for Ximluci® (ranibizumab) in November, a biosimilar to the reference drug Lucentis®. The approval followed the positive opinion the company received in September 2022 from the Committee for Medicinal Products for Human Use (CHMP). The marketing authorization for Ximluci® is held by Xbrane’s partner STADA Arzneimittel AG (STADA) and is valid in all 27 EU member states, as well as Iceland, Norway and Liechtenstein.
  • Xbrane reported in December plans to submit the Biologics License Application (BLA) to the FDA in Q1 2023.

Significant events after the end of the quarter

  • In January, marketing authorization was obtained for Ximluci® in the UK. STADA is preparing to launch Ximluci® in the UK in 2023


Xbrane Biopharma AB invites to a teleconference for investors, analysts and media on February the 17th, 2023, at 10.00 a.m. CET. To participate please follow the links below.

See below link and call-in details to the presentation below

Webcast URL
https://edge.media-server.com/mmc/p/syxw4qq6
 
Conference call dial in details, Participants:
Online Registration:
https://register.vevent.com/register/BI875d79843368447494c388901b23019e